ClinicalTrials.gg
CompletedNCT02217527UH3-P2Updated Aug 15, 2018Results posted

Test of Novel Drug for Smoking Cessation

A Phase 2 interventional study of Active JNJ Drug and Placebo pill in Smoking Cessation, sponsored by Chengappa, K.N. Roy, MD. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-15.

Sponsored by Chengappa, K.N. Roy, MD · Phase 2, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 921 studies in Smoking Cessation with a site in United States — 98 open to participants now, 127 under way, 7 of them phase 3. Smoking Cessation · United States.

Enrollment
712th of 873
36 · median 148
Started
2014
with 32 others
Phase 2
105 of 921
8 open now
Registered
414th of 921
by date

Among the 921 studies in Smoking Cessation with a site in United States, this one is the 712th largest by enrollment of the 873 interventional ones that give a count, is one of 33 that started in 2014, is one of 105 in phase 2, and was the 414th registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 197 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

98 of the 921 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 135 Smoking Cessation studies recruiting now, 93 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 921 studies in Smoking Cessation with a site in United States, or all of them as a file.
02

Study summary

The study will assess a novel active drug vs. placebo on ability to reduce smoking and aid cessation during a one-week "practice" quit period for each condition in smokers with a high interest in quitting (i.e. crossover design). Medication effects on reducing withdrawal and cognitive impairment will help assess the mechanism to support quit smoking attempts.

Read the detailed description

We aim to test the proof of principal that an alpha-7 PAM drug, JNJ-39393406, promotes smoking cessation when compared to placebo. We have developed, tested, and validated an efficient Phase 2a screening procedure that optimally combines the validity of randomized clinical trials with the practicality of lab- based medication studies. Notably, it employs a within-subject, cross-over design comparing active versus placebo effects on quitting smoking to maximize statistical power without a large sample, in contrast to the large samples needed for between-groups randomized treatment conditions. Using this procedure, we will evaluate effects of JNJ-39393406 vs. placebo on short-term smoking abstinence in smokers who already have a high interest in quitting soon. We predict that, compared with placebo, JNJ-39393406 will increase days of abstinence, identifying initial evidence of efficacy for smoking cessation. Our main dependent measure is days of very stringent biochemically validated (expired CO\<5 ppm) 24-hr smoking abstinence, with post-quit withdrawal and cognitive function as secondary measures. Potential for adverse side-effects will be assessed at each visit.

03

Conditions studied

  • Smoking Cessation

Browse trials for

Keywords

  • crossover
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy male and female dependent smokers wanting to quit soon

Exclusion criteria

-

Exclusion Criteria:

  • Use of non-smoked nicotine products
  • Already enrolled in cessation program.

    • Recent alcohol or substance dependence (≤ 3 months)
    • Women who are pregnant, planning a pregnancy, or lactating; all female participants shall undergo a pregnancy test at screening and will be excluded if positive.
    • Serious or unstable medical disorder within the past 3 months
  • Epilepsy

    • Current diagnosis (within last 6-months) of abnormal cardiac rhythms; unstable cardiovascular disease e.g. stroke, myocardial infarction in the last 6 months
    • Evidence impaired liver function test (LFT)
    • Evidence of kidney failure
    • Any subject with a history of hematological cancers examples: leukemia, lymphoma etc.
    • Any hematological laboratory abnormality.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    JNJ Active Drug

    200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.

    Drug: Active JNJ Drug · Drug: Placebo pill

  • Experimental
    Placebo Pill

    Placebo pill used for one week quit attempt, as part of crossover design.

    Drug: Active JNJ Drug · Drug: Placebo pill

Interventions

  • DrugJNJ-39393406Studies of JNJ-39393406JNJ-39393406 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.

    Also known as: JNJ-39393406

  • DrugPlacebo pill

    Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.

06

What researchers measure

Primary outcomes

  1. Quit Status

    Complete abstinence from smoking for 24 hr is counted as a "quit day" and is assessed daily from Mon-Fri for just one week, on the JNJ active drug and one week on placebo. This same Mon-Fri procedure for one week (only) is done for both drug phases. Total outcome in each drug condition therefore is number of quit days out of the five assessment days (range 0-5).

    Time frame: up to one week each drug phase (0-5)

Secondary outcomes

  1. Minnesota Nicotine Withdrawal Scale (MNWS) During Attempt to Quit on Active JNJ Drug and on Placebo

    Severity of withdrawal symptoms will be assessed with standard self-report measure of Minnesota Nicotine Withdrawal Scale (MNWS) each quit day during one week only on active JNJ, and each quit day during one week on placebo. Ratings are made on 0-100 visual analog scale, with 0="not at all" to 100="very much", and are averaged to create a total score also ranging from 0-100. Higher scores indicate more severe withdrawal.

    Time frame: only on days quit while on JNJ or on placebo

  2. Cognitive Function on Continuous Performance Task (CPT) for Those With CO<10 During First Assessment Day (Mon) of Attempt to Quit Smoking During Both JNJ and Plac Quit Periods

    This measure of cognitive performance (mean of median speed of correct responding on computer keyboard to letters and numbers) was assessed only on Monday (day 1) of the 0-5 days during each drug/placebo condition. Data only from those shown to have CO\<10 ppm were analyzed, to confirm responding during abstinence while on drug/placebo condition. Cognitive testing consisted of standard Continuous Performance Task (CPT), on active JNJ and on placebo phases. This measure is assessed to determine potential mechanism of drug efficacy in relieving disrupted cognitive processing function caused by tobacco deprivation and withdrawal.

    Time frame: first day during quit week on JNJ, and during quit week on placebo.

07

Results

Posted Aug 15, 2018
Limitations and caveats
Our findings could be specific to the brief duration, procedures used, and single dose tested in this cross-over study.

Participant flow

Drug Condition 1: First Study Phase
Participant flow — Drug Condition 1: First Study Phase
MilestoneOrder 1--JNJ Active Then PlacOrder 2--Placebo Then JNJ Active
Started1818
Completed1715
Not completed13
Withdrew: Withdrawal by subject13
Drug Condition 2: Second Study Phase
Participant flow — Drug Condition 2: Second Study Phase
MilestoneOrder 1--JNJ Active Then PlacOrder 2--Placebo Then JNJ Active
Started1715
Completed1714
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryQuit Status

Complete abstinence from smoking for 24 hr is counted as a "quit day" and is assessed daily from Mon-Fri for just one week, on the JNJ active drug and one week on placebo. This same Mon-Fri procedure for one week (only) is done for both drug phases. Total outcome in each drug condition therefore is number of quit days out of the five assessment days (range 0-5).

Time frame:
up to one week each drug phase (0-5)
Reported as:
Mean · number of days quit
Quit Status
number of days quitOrder 1--JNJ Active Then PlacOrder 2--Placebo Then JNJ Active
on JNJ0.5 ± 1.30.2 ± 0.6
on placebo0.7 ± 1.50.5 ± 1.0
SecondaryMinnesota Nicotine Withdrawal Scale (MNWS) During Attempt to Quit on Active JNJ Drug and on Placebo

Severity of withdrawal symptoms will be assessed with standard self-report measure of Minnesota Nicotine Withdrawal Scale (MNWS) each quit day during one week only on active JNJ, and each quit day during one week on placebo. Ratings are made on 0-100 visual analog scale, with 0="not at all" to 100="very much", and are averaged to create a total score also ranging from 0-100. Higher scores indicate more severe withdrawal.

Time frame:
only on days quit while on JNJ or on placebo
Reported as:
Mean · units on a scale
Minnesota Nicotine Withdrawal Scale (MNWS) During Attempt to Quit on Active JNJ Drug and on Placebo
units on a scaleOrder 1--JNJ Active Then PlacOrder 2--Placebo Then JNJ Active
on active JNJ12.4 ± 8.124.0 ± 23.4
on placebo15.5 ± 15.223.1 ± 19.8
SecondaryCognitive Function on Continuous Performance Task (CPT) for Those With CO<10 During First Assessment Day (Mon) of Attempt to Quit Smoking During Both JNJ and Plac Quit Periods

This measure of cognitive performance (mean of median speed of correct responding on computer keyboard to letters and numbers) was assessed only on Monday (day 1) of the 0-5 days during each drug/placebo condition. Data only from those shown to have CO\<10 ppm were analyzed, to confirm responding during abstinence while on drug/placebo condition. Cognitive testing consisted of standard Continuous Performance Task (CPT), on active JNJ and on placebo phases. This measure is assessed to determine potential mechanism of drug efficacy in relieving disrupted cognitive processing function caused by tobacco deprivation and withdrawal.

Time frame:
first day during quit week on JNJ, and during quit week on placebo.
Reported as:
Mean · ms time of correct responding
Cognitive Function on Continuous Performance Task (CPT) for Those With CO<10 During First Assessment Day (Mon) of Attempt to Quit Smoking During Both JNJ and Plac Quit Periods
ms time of correct respondingOrder 1--JNJ Active Then PlacOrder 2--Placebo Then JNJ Active
on active JNJ444.3 ± 69.3443.3 ± 32.0
on placebo434.2 ± 33.5439.2 ± 28.0

Adverse events

Collected over Assessed over the 2 weeks of med use on each condition (active JNJ, or placebo) per participant and ending within 1 week post-participation.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
While on Active JNJ0/36 (0%)0/36 (0%)5/36 (13.9%)
While on Placebo0/36 (0%)0/36 (0%)3/36 (8.3%)
Most frequent other events
Most frequent other events
EventWhile on Active JNJWhile on Placebo
self-reported nauseaGastrointestinal disorders3/360/36
Abnormal EKGCardiac disorders1/360/36
diarrheaGastrointestinal disorders1/360/36
self-reported skin rashSkin and subcutaneous tissue disorders0/361/36
swelling in feetMusculoskeletal and connective tissue disorders0/361/36
body achesGeneral disorders1/360/36
feeling of subjective panicGeneral disorders1/361/36
heart racingCardiac disorders0/361/36

Baseline characteristics

Healthy smokers interested in permanently quitting smoking within the next few months.

Age, Categorical
Age, Categorical(Participants)Order 1--JNJ Active Then PlacOrder 2--Placebo Then JNJ ActiveTotal
<=18 years000
Between 18 and 65 years181836
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Order 1--JNJ Active Then PlacOrder 2--Placebo Then JNJ ActiveTotal
Female91019
Male9817
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Order 1--JNJ Active Then PlacOrder 2--Placebo Then JNJ ActiveTotal
Hispanic or Latino000
Not Hispanic or Latino181836
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Order 1--JNJ Active Then PlacOrder 2--Placebo Then JNJ ActiveTotal
United States181836
Fagerstrom Test of Nicotine Dependence (FTND) scale score
Fagerstrom Test of Nicotine Dependence (FTND) scale score(units on a scale)Order 1--JNJ Active Then PlacOrder 2--Placebo Then JNJ ActiveTotal
Mean4.9 ± 1.54.9 ± 1.54.9 ± 1.5
08

Study locations

1 site
  • Univ of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Jul 2017 and a completion of Jan 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2014
First posted
Aug 15, 2014
Start
Nov 2014
Primary completionActual
Jul 2017
CompletionActual
Jan 2018
Results first posted
Aug 15, 2018
Last update
Aug 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02217527
Lead sponsor
Chengappa, K.N. Roy, MD
Responsible party
Kenneth A. Perkins, PhD. (Professor, University of Pittsburgh) — Principal investigator
First posted
Aug 15, 2014
Start date
Nov 2014
Primary completion
Jul 2017
Completion
Jan 2018
Results posted
Aug 15, 2018
Last update
Aug 15, 2018

Study contacts

Kenneth Perkins, PhD
principal investigator · Univ of PIttsburgh

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JNJ-39393406

Start the discussion